-
Chapter
Is Leukocyte Depletion Important in the Prevention of Alloimmunization by Random Single Donor Platelet Transfusion?
The major risk factor associated with repeated platelet transfusions is alloimmunization. Its management represents one of the greatest remaining clinical and research challenges in the field of platelet trans...
-
Article
Long-term plasma exchange in a case of Refsum's disease
Refsum's disease (Heredopathia atactica polyneuritiformis) is caused by accumulation of phytanic acid in all body tissues due to an inherited failure of alphaoxidation of branched chain fatty acids. Plasmapher...
-
Article
Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial
The use of granulocyte colony-stimulating factor (G-CSF) has been established to improve hematological recovery after allogeneic bone marrow transplantation (BMT). The optimal timing to start with G-CSF has no...
-
Article
Contrast media triggering cutaneous graft-versus-host disease
Adverse reactions to iodinated contrast media are varied and known to develop in patients with asthma and a history of allergy. We describe three successful allogeneic bone marrow transplantation (BMT) patient...
-
Article
Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation
Aside from causing hemolytic reactions the ABO blood group system does not have an impact on outcome after allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). However, only a few studie...
-
Article
Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial
Granulocyte colony-stimulating factor (G-CSF) is widely used to accelerate neutrophil recovery after allogeneic BMT or PBSC transplantation. The optimal time to start G-CSF treatment is not known. Forty-two pa...
-
Article
Quality control of a national bone marrow donor registry: results of a pilot study and proposal for a standardized approach
Unrelated hematopoietic stem cell transplantation (HSCT) is a recognized therapy for hematological diseases and over 8 million HLA-typed donors are ready to donate. Increased international exchanges and rapid ...
-
Article
Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland
It is currently unknown what degree of human leukocyte antigen (HLA)-mismatching is acceptable in unrelated donor hematopoietic stem cell transplantation (UD-HSCT). Mismatches at some loci may be more permissi...
-
Article
The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable
Identification of an unrelated HLA allele-matched hematopoietic stem cell (HSC) donor is a costly and time-consuming procedure. To improve search logistics, we have limited the search period to 6 months and ha...
-
Article
Effects of an outpatient physical exercise program on hematopoietic stem-cell transplantation recipients: a randomized clinical trial
Patients who undergo hematopoietic SCT (HSCT) often experience physical and psychological problems, even long after treatment has been completed. This study was performed to evaluate the effects of a 12-week o...
-
Article
Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT
Despite the introduction of novel drugs, cure of multiple myeloma remains rare. Allo-SCT can induce long-term remission, but randomized studies in advanced disease are lacking and the influence of novel drugs ...
-
Article
Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT
A considerable number of patients undergoing allogeneic hematopoietic SCT (HSCT) develop post-transplant complications requiring intensive care unit (ICU) treatment. Whereas the indications and the outcome of ...
-
Article
The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT
Several T-cell depletion (TCD) techniques are used for haploidentical hematopoietic SCT (HSCT), but direct comparisons are rare. We therefore studied the effect of in vitro TCD with graft engineering (CD34 select...
-
Article
Differences in health behaviour between recipients of allogeneic haematopoietic SCT and the general population: a matched control study
Little is known of health-relevant behaviour among long-term survivors of haematological disorders treated with haematopoietic SCT. This comparative cross-sectional multicentre study aimed (1) to explore the p...
-
Article
High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities
Unrelated donor searches in Switzerland require high-resolution HLA ty** for HLA-A/B/C/DRB1/DRB3,4/DQB1 loci. We evaluated this strategy accepting donors with ⩾9/10 match. Of 802 unrelated donor transplants ...
-
Article
Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
-
Article
Lack of association between relationship status and clinical outcome in allogeneic stem cell transplantation—the Swiss Transplant Cohort Study
-
Article
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a global approval and availability review
-
Article
Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors
Since July 2007 prospective life-long follow-up (FU) for unrelated (URD) and related donors (RD) is mandatory in Switzerland and data on every allogeneic haematopoietic progenitor cell (HPC) donation are colle...
